Skip to content

    Health X Platform Q1 FY27 earnings call

    HEALTHX
    Healthcare·11 Aug 2026
    Management Summary

    Health X Platform Limited delivered a strong Q1 FY27, marked by robust revenue growth across its core platforms and a return to positive PAT. Strategic investments in technology and geographical expansion are driving momentum, though management prioritizes long-term growth and cash flow over near-term EBITDA profitability. The company is expanding its infrastructure and expects continued strong growth, particularly from its high-margin JITO private label.

    Highlights

    5

    • Revenue from operations grew 58% Y-o-Y to INR 440 crores, and 16% Q-o-Q from INR 378 crores.

    • Gross profit increased 64% Y-o-Y and 24% Q-o-Q to INR 34 crores, with gross margin improving to 7.8% from 7.3% in Q4 FY26.

    • PAT turned positive at INR 2 crores in Q1 FY27, a significant improvement from a negative INR 13 crores loss in Q4 FY26.

    • RetailerShakti, the principal growth engine, grew 48% Y-o-Y, and SastaSundar grew 44% Y-o-Y.

    • JITO private label sales grew from INR 25 lakhs in Q4 FY26 to INR 79 lakhs in Q1 FY27, demonstrating 216% QoQ growth with gross margins above 50%.

    Concerns

    3

    • EBITDA remained slightly impacted by higher employee and other operating expenses, resulting in a loss of INR 15 crores.

    • Profitability (PAT of INR 2 crores) remained below the INR 26 crores PAT reported in Q1 FY26.

    • Management stated that the company is not expected to be EBITDA positive for the next two to three years, as EBITDA is not their primary focus.

    Key financials

    Single quarter

    06 metrics
    1. 01Revenue from Operations₹440 Cr+58.0%YoY
    2. 02Gross Profit₹34 Cr+64%YoY
    3. 03Gross Margin7.8%+0.5%QoQ
    4. 04EBITDA₹-15 Cr+25%QoQ
    5. 05EBITDA Margin-3.4%+2.1%QoQ

    Segment breakdown

    Revenue GrowthGross Margin
    RetailerShakti48%7.8%
    SastaSundar44%—
    JITO (Private Label)—50%
    Heatmap· 2 shared metrics

    Capital allocation

    2
    medium confidence
    CategoryHeadline
    Capex

    Capex disclosed

    Debt

    Debt disclosed

    Guidance & targets

    10
    CategoryTargetPriority
    Revenue
    Monthly Revenue (July 2026)
    INR 150 crores+
    		High
    Gross Margin
    Overall Gross Margin
    8% plus
    		High
    Gross Margin
    Long-term Gross Margin (B2B & B2C)
    12%
    		Medium
    Profitability
    RetailerShakti EBITDA
    Positive EBITDA
    		High
    Profitability
    Company-wide EBITDA Positive Status
    Not EBITDA positive
    		High
    Market Share
    West Bengal Market Share
    7%
    		High
    Wallet Share
    RetailerShakti Average Wallet Share
    Double current share (~4%)
    		Medium
    Inventory Management
    Retailer Inventory Days
    5-6 days
    		Medium
    Infrastructure
    Existing Infrastructure Capacity
    Support 100% growth (INR 2500-3000 crores revenue)
    		High
    Regulatory
    SEBI Approval for Merger/Demerger Scheme
    On track
    		High

    What to watch in Q2 FY27

    5

    RetailerShakti EBITDA Status

    Q3 FY27
    CurrentCloser to break-even
    TargetPositive EBITDA

    Why it matters

    RetailerShakti is the principal growth engine, and achieving positive EBITDA will demonstrate improving unit economics.

    EBITDA number we are closer to break even and expect to make positive EBITDA in Q3 this financial year end.

    Risks & concerns

    3
    RiskSeverity

    EBITDA impact from operating expenses

    EBITDA remained slightly impacted by higher employee and other operating expenses in Q1 FY27. — Management acknowledged

    medium

    Profitability below prior year's Q1

    Q1 FY27 PAT of INR 2 crores is significantly lower than Q1 FY26 PAT of INR 26 crores. — Management acknowledged

    medium

    Long-term EBITDA profitability not a priority

    Management states the company is not expected to be EBITDA positive for the next 2-3 years, as their priority is building a large company and cash flow, not immediate EBITDA. — Management acknowledged

    medium

    Q&A highlights

    8

    “So in Q1 FY27 at RetailerShakti, we are maintaining a gross margin of around 7.8% and EBITDA number we are closer to break even and expect to make positive EBITDA in Q3 this financial year end.”

    Provides specific segment-level profitability metrics and a clear timeline for positive EBITDA for the core growth engine.

    asked by Sanchita Sood

    2 min read6 chapters

    Detailed Narrative

    01

    Strong Revenue Momentum and Profitability Turnaround

    Health X Platform Limited reported a robust Q1 FY27, with revenue from operations growing 58% year-on-year and 16% quarter-on-quarter to INR 440 crores. This strong top-line performance was accompanied by a 64% year-on-year increase in gross profit to INR 34 crores, with gross margin improving to 7.8% from 7.3% in the previous quarter. A significant highlight was the company's return to positive PAT, recording INR 2 crores in Q1 FY27, a substantial improvement from the negative INR 13 crores loss in Q4 FY26.

    02

    Core Platforms Driving Growth and Market Penetration

    Both RetailerShakti and SastaSundar platforms were key drivers of growth. RetailerShakti, the principal growth engine, achieved 48% year-on-year revenue growth, while SastaSundar, reflecting a strong B2C business, grew 44% year-on-year. A significant portion of business for both platforms, 67% for RetailerShakti and 78% for SastaSundar, originates from tier 2 and tier 3 markets, reinforcing the company's philosophy of inclusive healthcare infrastructure. RetailerShakti is expected to achieve positive EBITDA by Q3 FY27.

    03

    Strategic Geographical Expansion and New Market Entry

    The company is actively expanding its footprint beyond existing markets, replicating its successful model across new geographies. From its West Bengal base, Health X has expanded into Odisha, Bihar, and Jharkhand. Northern operations have been strengthened with expansion into Haryana and UP from Noida. The Northeast region, including Assam, is highlighted as the highest-growing entity, demonstrating the model's scalability and strong response in underpenetrated areas.

    04

    JITO Private Label: High-Margin Growth Opportunity

    The new JITO private label initiative is gaining significant momentum, with sales growing from INR 25 lakhs in Q4 FY26 to INR 79 lakhs in Q1 FY27, representing a 216% quarter-on-quarter increase. JITO products offer a gross margin above 50%, providing a substantial opportunity to enhance overall platform margins and make quality healthcare more affordable. Management anticipates JITO's contribution to surpass internal projections, further boosting profitability.

    05

    Technology Investment and Capital Efficiency Focus

    Health X is making strategic investments in technology, including the development of an AI-monitored RetailAir product for retailers and AI technology for SastaSundar. These technology investments are currently contributing to EBITDA losses for SastaSundar, but management views them as crucial for long-term growth and efficiency. The company maintains a capital-efficient model, with a working capital cycle of approximately 28 days (8% of revenue), prioritizing building a large, scalable company with strong cash flow over immediate EBITDA profitability.

    06

    Infrastructure Development and Owned Last-Mile Delivery

    The company is strengthening its fulfilment infrastructure with new capabilities in Guwahati, Lucknow, and Udaipur. The Noida warehouse is already operational, and new warehouses are planned or under construction in Guwahati (75,000 sq ft, starting in 6 months), Patna, and Lucknow (starting in 2-3 months). Existing infrastructure can support 100% growth (up to INR 2500-3000 crores revenue) for FY28. Health X employs its own riders for last-mile delivery, treating them as full-time employees to ensure reliability and quality control for pharmaceutical products, avoiding third-party dependencies.

    This is an AI-generated summary of a publicly available earnings call transcript.